Six New Drugs Get EMA Nod, Radius and Portola To Fight Rejections

Two products that the European Medicines Agency this week said should not be authorized for sale in the EU are already approved in the US.

3d render of Europe map Earth globe
Six new drugs received a recommendation for EU approval this month

The European Medicines Agency has recommended for EU marketing approval six products, including as expected Clovis Oncology’s new ovarian cancer drug Rubraca (rucaparib). Among other things, the agency rejected marketing authorization applications (MAAs) for two drugs that are already approved in the US and upheld a negative opinion it adopted last December for another product.

The other five MAAs that this week received positive opinions for pan-EU approval from the EMA’s key scientific committee, the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet